Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 3
1963 3
1964 3
1965 3
1966 1
1967 1
1968 4
1970 4
1977 1
1978 1
1979 1
1981 1
1983 4
1984 5
1985 5
1986 7
1987 10
1988 12
1989 12
1990 6
1991 8
1992 12
1993 9
1994 5
1995 11
1996 8
1997 9
1998 20
1999 19
2000 16
2001 26
2002 14
2003 16
2004 20
2005 21
2006 21
2007 24
2008 24
2009 26
2010 35
2011 33
2012 37
2013 54
2014 48
2015 57
2016 73
2017 80
2018 65
2019 66
2020 70
2021 57
2022 65
2023 44

Text availability

Article attribute

Article type

Publication date

Search Results

1,062 results

Results by year

Filters applied: . Clear all
Page 1
Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis.
Nishikawa H, Enomoto H, Nishiguchi S, Iijima H. Nishikawa H, et al. Among authors: iijima h. Int J Mol Sci. 2020 Jul 24;21(15):5254. doi: 10.3390/ijms21155254. Int J Mol Sci. 2020. PMID: 32722100 Free PMC article. Review.
Lysophosphatidylserines derived from microbiota in Crohn's disease elicit pathological Th1 response.
Otake-Kasamoto Y, Kayama H, Kishikawa T, Shinzaki S, Tashiro T, Amano T, Tani M, Yoshihara T, Li B, Tani H, Liu L, Hayashi A, Okuzaki D, Motooka D, Nakamura S, Okada Y, Iijima H, Takeda K, Takehara T. Otake-Kasamoto Y, et al. Among authors: iijima h. J Exp Med. 2022 Jul 4;219(7):e20211291. doi: 10.1084/jem.20211291. Epub 2022 May 24. J Exp Med. 2022. PMID: 35608941 Free PMC article.
Home exercise therapy to improve muscle strength and joint flexibility effectively treats pre-radiographic knee OA in community-dwelling elderly: a randomized controlled trial.
Suzuki Y, Iijima H, Tashiro Y, Kajiwara Y, Zeidan H, Shimoura K, Nishida Y, Bito T, Nakai K, Tatsumi M, Yoshimi S, Tsuboyama T, Aoyama T. Suzuki Y, et al. Among authors: iijima h. Clin Rheumatol. 2019 Jan;38(1):133-141. doi: 10.1007/s10067-018-4263-3. Epub 2018 Aug 30. Clin Rheumatol. 2019. PMID: 30167975 Free PMC article. Clinical Trial.
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
Rimini M, Rimassa L, Ueshima K, Burgio V, Shigeo S, Tada T, Suda G, Yoo C, Cheon J, Pinato DJ, Lonardi S, Scartozzi M, Iavarone M, Di Costanzo GG, Marra F, Soldà C, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Pressiani T, Nishida N, Iwamoto H, Sakamoto N, Ryoo BY, Chon HJ, Claudia F, Niizeki T, Sho T, Kang B, D'Alessio A, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimur T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Pedica F, De Cobelli F, Ratti F, Aldrighetti L, Kudo M, Cascinu S, Casadei-Gardini A. Rimini M, et al. Among authors: iijima h. ESMO Open. 2022 Dec;7(6):100591. doi: 10.1016/j.esmoop.2022.100591. Epub 2022 Oct 6. ESMO Open. 2022. PMID: 36208496 Free PMC article.
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.
Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Soldà C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Persano M, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Cascinu S, Cucchetti A. Casadei-Gardini A, et al. Among authors: iijima h. Eur J Cancer. 2023 Feb;180:9-20. doi: 10.1016/j.ejca.2022.11.017. Epub 2022 Nov 25. Eur J Cancer. 2023. PMID: 36527976 Clinical Trial.
Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis.
Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Naganuma A, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Tada T, et al. Among authors: iijima h. Cancer Med. 2022 Oct;11(20):3796-3808. doi: 10.1002/cam4.4763. Epub 2022 Apr 19. Cancer Med. 2022. PMID: 35441477 Free PMC article.
Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Kosaka H, Shibata H, Aoki T, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Kaibori M, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Hiraoka A, et al. Among authors: iijima h. Cancer Med. 2023 Jan;12(1):325-334. doi: 10.1002/cam4.4854. Epub 2022 Jun 3. Cancer Med. 2023. PMID: 35666040 Free PMC article.
1,062 results